









市場
/
株式
/
nasdaq-anik
/

Anika Therapeutics Inc

ANIK

9.546USD

-0.024-0.25%

取引時間（ET）15分遅れの株価

137.67M時価総額

損失額直近12ヶ月PER



Anika Therapeutics Inc

9.546

-0.024-0.25%

概要企業名金融分析

概要

企業名

金融

分析

詳細情報 Anika Therapeutics Inc 企業名

Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.

Anika Therapeutics Incの企業情報



企業コードANIK

会社名Anika Therapeutics Inc

上場日May 16, 1985

最高経営責任者「CEO」Blanchard (Cheryl Renee)

従業員数288

証券種類Ordinary Share

決算期末May 16

本社所在地32 Wiggins Ave

都市BEDFORD

証券取引所NASDAQ OMX - NASDAQ BASIC

国United States of America

郵便番号01730-2315

電話番号17814579000

ウェブサイトhttps://anika.com/

企業コードANIK

上場日May 16, 1985

最高経営責任者「CEO」Blanchard (Cheryl Renee)

Anika Therapeutics Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Glenn R. Larsen, Ph.D.

Independent Director

50.26K

+39.24%

Ms. Sheryl L. Conley

Independent Director

39.84K

+55.16%

Mr. William R. (Bill) Jellison

Independent Director

23.10K

+158.45%

Mr. Joseph H. (Joe) Capper

Independent Director

20.40K

+227.02%

Mr. Stephen D. (Steve) Griffin

Chief Financial Officer, Chief Operating Officer, Executive Vice President

9.07K

Mr. Matt Hall

Director, Corporate Development and Investor Relations

Mr. Ian McLeod

Chief Accounting Officer, Vice President, Treasurer

Mr. Gary P. Fischetti

Independent Director

Dr. Cheryl Renee Blanchard, Ph.D.

President, Chief Executive Officer, Director

Mr. David B. Colleran, J.D.

Executive Vice President, General Counsel, Secretary

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Glenn R. Larsen, Ph.D.

Independent Director

50.26K

+39.24%

Ms. Sheryl L. Conley

Independent Director

39.84K

+55.16%

Mr. William R. (Bill) Jellison

Independent Director

23.10K

+158.45%

Mr. Joseph H. (Joe) Capper

Independent Director

20.40K

+227.02%

Mr. Stephen D. (Steve) Griffin

Chief Financial Officer, Chief Operating Officer, Executive Vice President

9.07K

Mr. Matt Hall

Director, Corporate Development and Investor Relations

収益内訳

通貨: USD更新時刻: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

OEM Channel

16.34M

57.90%

Commercial Channel

11.88M

42.10%

地域別USD

会社名

収益

比率

United States

17.92M

63.52%

Other

5.54M

19.64%

Europe

4.75M

16.84%

事業別

地域別

事業別USD

会社名

収益

比率

OEM Channel

16.34M

57.90%

Commercial Channel

11.88M

42.10%

株主

更新時刻: Thu, Dec 4

株主統計

種類

株主統計

比率

Trigran Investments, Inc.

11.24%

Caligan Partners, LP

9.95%

BlackRock Institutional Trust Company, N.A.

6.38%

The Vanguard Group, Inc.

5.41%

BlackRock Financial Management, Inc.

5.38%

他の

61.63%

株主統計

比率

Trigran Investments, Inc.

11.24%

Caligan Partners, LP

9.95%

BlackRock Institutional Trust Company, N.A.

6.38%

The Vanguard Group, Inc.

5.41%

BlackRock Financial Management, Inc.

5.38%

他の

61.63%

種類

株主統計

比率

Hedge Fund

29.85%

Investment Advisor/Hedge Fund

27.73%

Investment Advisor

25.43%

Individual Investor

4.88%

Research Firm

2.02%

Pension Fund

0.51%

Bank and Trust

0.12%

Venture Capital

0.09%

他の

9.38%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

245

12.37M

97.19%

-666.00

2025Q3

267

12.37M

100.32%

-461.27K

2025Q2

295

12.88M

103.23%

-71.30K

2025Q1

297

12.95M

103.38%

-1.70M

2024Q4

298

12.83M

102.20%

-560.99K

2024Q3

297

13.48M

104.72%

-150.44K

2024Q2

301

13.64M

105.78%

+30.78K

2024Q1

301

13.61M

105.08%

-1.78M

2023Q4

304

13.45M

105.34%

+303.47K

2023Q3

297

13.16M

105.14%

-356.42K

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

Trigran Investments, Inc.

2.04M

14.12%

-5.34K

-0.26%

Jun 30, 2025

Caligan Partners, LP

1.44M

9.95%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

937.30K

6.5%

-20.13K

-2.10%

Jun 30, 2025

The Vanguard Group, Inc.

779.47K

5.41%

+2.07K

+0.27%

Jun 30, 2025

BlackRock Financial Management, Inc.

546.12K

3.79%

+24.11K

+4.62%

Jun 30, 2025

Acadian Asset Management LLC

575.64K

3.99%

+36.03K

+6.68%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

623.08K

4.32%

+9.11K

+1.48%

Jun 30, 2025

The Capital Management Corporation

408.85K

2.84%

+79.19K

+24.02%

Jun 30, 2025

Boothbay Fund Management, LLC

529.50K

3.67%

Jun 30, 2025

Renaissance Technologies LLC

527.22K

3.66%

-1.40K

-0.26%

Jun 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 0.00 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

データなし

株式分割



日付

種類

比率

データなし

日付

種類

比率

データなし

よくある質問

Anika Therapeutics Incの上位5名の株主は誰ですか？



Anika Therapeutics Incの上位5名の株主は以下のとおりです。
Trigran Investments, Inc.は2.04M株を保有しており、これは全体の14.12%に相当します。
Caligan Partners, LPは1.44M株を保有しており、これは全体の9.95%に相当します。
BlackRock Institutional Trust Company, N.A.は937.30K株を保有しており、これは全体の6.50%に相当します。
The Vanguard Group, Inc.は779.47K株を保有しており、これは全体の5.41%に相当します。
BlackRock Financial Management, Inc.は546.12K株を保有しており、これは全体の3.79%に相当します。